申请人:Bexel Pharmaceuticals, Inc.
公开号:US07521465B2
公开(公告)日:2009-04-21
Novel diphenyl ether derivatives are provided that exhibit activity useful for reducing glucose, cholesterol, and/or triglyceride levels in plasma, and for treatment of obesity, inflammation, immunological diseases, autoimmune diseases, diabetes and disorders associated with insulin resistance.
提供了一种新型的二苯醚衍生物,其表现出有用于降低血浆中葡萄糖、胆固醇和/或甘油三酯水平的活性,以及用于治疗肥胖、炎症、免疫性疾病、自身免疫疾病、糖尿病和与胰岛素抵抗有关的疾病的活性。